EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Erythropoietin Suppresses the Hepatic Fibrosis Caused by Thioacetamide: Role of the PI3K/Akt and TLR4 Signaling Pathways

Marawan A Elbaset iD, Bassim M S A Mohamed iD, Passant E Moustafa iD, Dina F Mansour iD, Sherif M Afifi, Tuba Esatbeyoglu iD, Sahar S M Abdelrahman iD, Hany M Fayed iD

Oxidative Medicine and Cellular Longevity · 22.08.2023 · 2023 · 1-14

DOI: 10.1155/2023/5514248 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oxidative Medicine and Cellular Longevity, erschienen am 22.08.2023. Verfasst von Marawan A Elbaset und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacology Department, Medical Research and Clinical Studies Institute, National Research Centre, 33 El-Bohouth St., Dokki, P.O. Box 12622, Cairo, …. Hauptthemen laut MEDLINE: Phosphatidylinositol 3-Kinases, Erythropoietin. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Leibniz Universität Hannover.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Erythropoietin (EPO) is recognized for its function in erythropoiesis; however, its potential antifibrotic effect against liver fibrosis remains unknown. This study examined whether EPO affects thioacetamide (TAA)-induced liver fibrosis by concentrating on the Toll-like receptor 4 (TLR4) cascade and the phosphatidylinositol 3-kinase (PI3K)/Akt pathway as possible pathways. Male Wistar rats were randomized into four groups, which included: the negative control group, the TAA group (intraperitoneal; TAA 100 mg/kg three times per week for 2 weeks), and EPO-treated groups (150 and 300 IU/kg, i.p.) for 2 weeks after TAA injections. EPO attenuated hepatic fibrosis in a dosage-dependent way, as manifested by the diminution in serum alanine aminotransferase and aspartate aminotransferase activities, as well as the increase in albumin level. EPO inhibited the increase in tissue levels of tumor necrosis factors-α, interleukin-1β, transforming growth factor-β1, and TLR4 and raised tissue levels of PI3K and p-PI3K. EPO antioxidant properties were demonstrated by restoring hepatic glutathione and superoxide dismutase by preventing the accumulation of hepatic malondialdehyde. Further, EPO increased the protein expression of PI3K and Akt and decreased TLR4 protein expression. Immunohistochemically, EPO treatment altered tissue histology and downregulated mitogen-activated protein kinase protein expression. Overall, the research suggested that EPO could prevent TAA-induced hepatic fibrosis through upregulating the PI3K/Akt signaling cascade and downregulation the TLR4 downstream axis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphatidylinositol 3-KinasesErythropoietinMaleRatsAnimalsRats, WistarProto-Oncogene Proteins c-aktThioacetamidePhosphatidylinositol 3-KinaseToll-Like Receptor 4Liver CirrhosisSignal Transduction

Substanzen

Phosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktThioacetamidePhosphatidylinositol 3-KinaseToll-Like Receptor 4Erythropoietin

Autor:innen und Institutionen

  • Pharmacology Department, Medical Research and Clinical Studies Institute, National Research Centre, 33 El-Bohouth St., Dokki, P.O. Box 12622, Cairo, Egypt.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Galala University, Attaka, Suez, Egypt.
  • Pharmacognosy Department, Faculty of Pharmacy, University of Sadat City, Sadat City 32897, Egypt.
  • Department of Food Development and Food Quality, Institute of Food Science and Human Nutrition, Gottfried Wilhelm Leibniz University Hannover, Am Kleinen Felde 30, Hannover 30167, Germany.
  • Department of Pathology, College of Veterinary Medicine, Cairo University, P.O. Box 12211, Cairo, Egypt.

ORCID-Profile: Marawan A Elbaset, Bassim M S A Mohamed, Passant E Moustafa, Dina F Mansour, Tuba Esatbeyoglu, Sahar S M Abdelrahman, Hany M Fayed

Förderung

  • Leibniz Universität Hannover

Zitieren

APA

Elbaset, M. A., Mohamed, B. M. S. A., Moustafa, P. E., Mansour, D. F., Afifi, S. M., Esatbeyoglu, T., Abdelrahman, S. S. M., & Fayed, H. M. (2023). Erythropoietin Suppresses the Hepatic Fibrosis Caused by Thioacetamide: Role of the PI3K/Akt and TLR4 Signaling Pathways. Oxidative Medicine and Cellular Longevity, 2023, 1-14. https://doi.org/10.1155/2023/5514248

Vancouver

Elbaset MA, Mohamed BMSA, Moustafa PE, Mansour DF, Afifi SM, Esatbeyoglu T, et al. Erythropoietin Suppresses the Hepatic Fibrosis Caused by Thioacetamide: Role of the PI3K/Akt and TLR4 Signaling Pathways. Oxidative Medicine and Cellular Longevity. 2023;2023:1-14. doi:10.1155/2023/5514248

BibTeX
@article{Elbaset2023,
  author = {Elbaset, Marawan A and Mohamed, Bassim M S A and Moustafa, Passant E and Mansour, Dina F and Afifi, Sherif M and Esatbeyoglu, Tuba and Abdelrahman, Sahar S M and Fayed, Hany M},
  title = {Erythropoietin Suppresses the Hepatic Fibrosis Caused by Thioacetamide: Role of the PI3K/Akt and TLR4 Signaling Pathways},
  journal = {Oxidative Medicine and Cellular Longevity},
  year = {2023},
  volume = {2023},
  pages = {1--14},
  doi = {10.1155/2023/5514248}
}
Kostenlos starten →